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Colorectal cancer is a common cause of death throughout the
world, and lymph nodes metastasis is an important prognostic
factor (Dukes and Bussey, 1958; Newland et al, 1981; Chapuis et
al, 1985; Fielding et al, 1986). The 5-year survival rate in patients
with colorectal cancer with lymph nodes metastasis is worse than
those without lymph nodes metastasis (Hermanek, 1995).
VEGF-C was initially identified to be a factor stimulating tyro-
sine kinase receptor Flt4 (VEGFR-3), which was purified from
PC-3 prostatic adenocarcinoma cells (Joukov et al, 1996). The
VEGF-C gene is localized on chromosome 4q34 (Paavonen et al,
1996) and has a high degree of homology to VEGF (Joukov et al,
1997). The open reading frame of VEGF-C c-DNA encodes a
protein of 419 amino acid residues, with a predicted molecular
mass of 46.9kDa (Joukov et al, 1997). Its mRNA is 2.4 and 2.0 kb
(Joukov et al, 1997), which is expressed in human adult tissues,
including heart, placenta, muscle, ovary, and small intestine
(Joukov et al, 1996). The expression of VEGF-C was also detected
in several types of malignant tumours (Salven et al, 1998). VEGF-
C is a ligand for VEGFR-3, which is predominantly expressed in
the endothelium of lymphatic vessels (Kaipainen et al, 1995; Kukk
et al, 1996), and VEGF-C is considered to be both a specific
marker for lymphatic endothelial cells and a specific factor for
lymphangiogenesis.
To date, only a few clinicopathological studies on VEGF-C
expression in malignant tumours have been reported (Ohta et al,
1999; Tsurusaki et al, 1999; Valtola et al, 1999; Yonemura et al,
1999).
To better understand the mechanism of lymph nodes metastasis
in cases of colorectal cancer, we examined the relationship
between expression of VEGF-C and clinicopathological features,
using immunohistochemical techniques and RT-PCR. Our data
show a strong correlation between VEGF-C expressions and
lymph nodes metastasis.
MATERIALS AND METHODS
Tissue specimens
We studied 99 Japanese colorectal cancer patients who had been
surgically treated in Department of Surgery and Science, Graduate
School of Medical Sciences, Kyushu University, Fukuoka, Japan
between 1991 and 1995. Age of the patients ranged from 15 to 89
years (mean 63 years), and 57 were men and 42 were women. For
immunohistochemistry, tissue specimens were obtained from all
99 primary colorectal cancers, and lymph nodes specimens with
metastatic tumours were selected from 18 cases.
For RNA extraction, 17 pairs of resected primary colorectal
carcinoma tissue and corresponding normal tissues were immedi-
ately placed in liquid nitrogen. No patient had been given neo-
adjuvant or adjuvant therapy. All pathological and histological
classifications of the tumours were based on the TNM classifica-
tion (Sobin and Wittekind, 1997).
Immunohistochemistry
The surgical specimens were fixed in 10% formalin solution and
embedded in paraffin. Histological slices of 3 mm were prepared,
then were deparaffined in xylene, and dehydrated with ethanol.
Endogenous peroxidase was blocked with 0.3% H2O2 in methanol
for 20 min at room temperature. After washing with phosphate-
buffered saline (PBS), non-specific binding was blocked by
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ature. Anti-VEGF-C antibody (goat, polyclonal. Santa Cruz,
California) was applied on the histological sections at a dilution of
1:50 and incubated in a moist chamber overnight at 4°C. After
washing the specimens with PBS, the slides were incubated in
biotinylated rabbit anti-goat antibody for 20 minutes at room
temperature. After three washes in the PBS, sections were incu-
bated in streptavidin-peroxidase reagent for 5 minutes at room
temperature. VEGF-C antigen was developed using diaminobenzi-
dine (Merck, Germany) and 2 mM hydrogen peroxide in 0.05%
PBS for 3 min at room temperature. For counterstaining, we used
Mayer’s Hematoxylin. A negative control was achieved by adding
a blocking peptide (Santa Cruz, California) to the primary
antibody. No staining was observed in the section.
Evaluation of immunoreactivity
Results of the immunohistochemical staining were evaluated by a
pathologist blinded to all clinical data. To evaluate the protein
expression, the results were graded as follows: (+) over 10% of the
neoplastic cells were stained, (–) completely negative. In this
study, (–) and (±) were classified as negative, (+) was classified as
positive.
Microvessel staining and counting
For microvessel staining, we randomly selected 20 samples from
the VEGF-C positive and negative groups, respectively. The
method of microvessel staining and counting were done as
described (Tomisaki et al, 1996). Briefly, intratumoral microves-
sels were highlighted by immunostaining with a mouse Mab
against CD34 (Novocastra, UK) in a 1:100 dilution and incubated
overnight at 4°C. Any single brown-stained cell or cluster of
endothelial cells clearly separated from adjacent vessels, tumour
cells and other connective tissue elements were considered to be a
microvessel. The stained sections were screened at ´40 magnifica-
tion to identify regions of highest vascular density within the
tumour. Vessels were counted in the 3 regions of highest vascular
density at ´200 magnification (0.739 m m2 per field) The
microvessel numbers were the mean number of vessels in these
areas.
RT-PCR amplification
Total RNA was isolated using ISOGEN (Nippon Gene, Inc,
Tokyo, Japan) RNA extraction kit and reverse-transcribed using
murine leukaemia virus reverse transcriptase. Quantity and quality
of mRNA from all samples were certified by RT-PCR amplifica-
tion of the GAPDH gene. Amplifications of VEGF-C transcripts
(763-bp) were done using the Perkin-Elmer GeneAmp PCR
system 9700 (Norwalk, CT, USA) and oligodeoxynucleotide
primers (forward; 5¢-ACCTGCCCCACCAATTACA-3¢, reverse;
5¢-GCCTCTTGTAAAGACTGGTT-3¢). These primers for VEGF-
C were designed from previously published sequences
(Wartiovaara et al, 1998). Thermal conditions of the system were
as follows; one cycle at 95°C for 5 min; 35 cycles at 95°C for
1 min, 52°C for 1 min, 72°C for 1.5 min; one cycle at 72°C for
7 min. The amplified DNA fragment was electrophoresed on 1.2%
agarose gels containing ethidium bromide with a DNA molecular
weight marker for comparison.
Statistical analysis
The BMDP Statistical Package program (BMDP, Los Angeles,
CA) for the main frame computer (4381; IBM, Armonk, NY) was
used for all analyses. Associations between the variables were
tested using Student’s t-test or Fisher’s exact probability test. The
BMDP LR program was used for multivariate adjustments for all
covariates simultaneously, with a backward stepwise logistic
regression analysis.
RESULTS
Immunohistochemistry
In specimens of normal colorectal mucosa, no VEGF-C protein
was stained. Among the 99 examined tumours, 55 showed VEGF-
C protein expression in the cytoplasm (Figure 1A). However, no
expression was observed in the nucleus area. In 44 of 99 colorectal
cancer specimens, VEGF-C was not expressed. The relationship
between VEGF-C expression and clinicopathological features is
given in Table 1. The positive expression of VEGF-C was signifi-
cantly higher (P = 0.0032) in tumours with lymphatic involvement
(50.9%) than in those without lymphatic involvement (29.5%).
The positive expression of VEGF-C was significantly higher
(P = 0.0025) in tumours with lymph nodes metastasis (60.0%)
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Figure 1 (A) Positive immunoreactivity for VEGF-C (primary tumour).
Magnification ´100. (B) Positive immunoreactivity for VEGF-C (metastatic
lymph nodes). Magnification ´200than in those without lymph nodes metastasis (29.5%). The rate of
positive expression of VEGF-C also increased with the depth of
tumour invasion (P = 0.0359). Correlation among gender of the
patients, histologic type, venous involvement, liver metastasis and
microvessel numbers was nil.
Multivariate analyses showed VEGF-C expression to be an
independent factor influencing both lymphatic involvement and
lymph nodes metastasis (Table 2).
The expression of VEGF-C in metastatic tumours in lymph
nodes was compared with that in primary tumours. Among the 18
cases examined (47 metastatic lymph nodes), 13 (40 metastatic
lymph nodes) showed a positive expression of VEGF-C protein.
VEGF-C was expressed in the cytoplasm of metastatic cancer
cells, and was the same as expression in the primary tumours
(Figure 1B). The relationship between VEGF-C expression in
primary tumours and that in metastatic lymph nodes is given in
Table 3. The expression of VEGF-C in metastatic lymph nodes
was fairly consistent with expression in the primary tumour.
Five-year survival for the patient population was 73 percent,
and survival rates were poorer for patients in the VEGF-C positive
VEGF-C expression in colorectal cancer 889
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Table 1 Expression of VEGF-C and clinicopathological features 
VEGF-C expression
n Positive Negative P value
Mean age (yrs) ± SD 61.8 ± 12.9 64.0 ± 11.1 NS
Gender NS
Men 57 28 29
Women 42 27 15
Tumour diameter (mm) ± SD 49.4 ± 17.8 44.4 ± 24.1 NS
Histologic type NS
Well 45 27 18
Moderately 47 25 22
Poorly 7 3 4
Depth of invasion 0.0359
Tis,T1,T2 18 6 12
T3,T4 81 49 32
Lymphatic involvement 0.0032
Negative 58 27 31
Positive 41 28 13
Venous involvement NS
Negative 54 29 25
Positive 45 26 19
Lymph nodes metastasis 0.0025
Negative 53 22 31
Positive 46 33 13
Liver metastasis NS
Negative 89 47 42
Positive 10 8 2
Microvessel numbers 64.9 ± 15.1 67.9 ± 14.6 NS
NS, no significant difference; SD, standard deviation
Table 2 Multivariate analyses with respect to lymphatic involvement and
lymph nodes metastasis
Variable Relative risk P value
Lymphatic involvement
Venous involvement 9.62 0.0001
Lymph nodes metastasis 3.33 0.0187
VEGF-C 3.24 0.028
Lymph nodes metastasis
Lymphatic involvement 4.86 0.0002
VEGF-C 3.26 0.006
Table 3 Relationship between VEGF-C expression in primary tumours and
that in metastatic lymph nodes
Primary tumours
Positive Negative P value
(n = 12) (n = 6)
Metastatic lymph nodes + 11 2 0.0217
Metastatic lymph nodes – 1 4
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Figure 2 Survival curves for patients with colorectal cancer, based on the
expression of VEGF-C. There were 55 patients with positive expression of
VEGF-C (dark line) and 44 patients with negative expression of VEGF-C
(light line), with no statistical differences in survival between the two groupsgroup than those in the negative group, but the difference was not
statistically significant (Figure 2).
mRNA expression
17 pairs of primary colorectal carcinoma tissue and corresponding
normal tissue were examined to verify VEGF-C mRNA expres-
sion. RT-PCR was done using primers of VEGF-C and those of
GAPDH as a internal control. Figure 3 shows examples of VEGF-
C mRNA expression. Seven of 10 VEGF-C protein positive cases
showed VEGF-C mRNA expression, on the other hand, only one
of seven VEGF-C protein negative cases showed VEGF-C mRNA
expression. The expression of VEGF-C mRNA was mostly
correlated with that of VEGF-C protein expression.
DISCUSSION
In this study, VEGF-C was highly expressed in the primary tumour
of patients with both lymph nodes metastasis and lymphatic
involvement, and VEGF-C expression increased in the metastatic
tumour of lymph nodes, as compared with findings in the primary
tumour. On the other hand; the expression of VEGF-C was not
related to hematogenous metastasis, such as liver metastasis or
venous involvement. These findings suggest that VEGF-C was
functionally associated with lymphatic involvement and lymph
nodes metastasis.
There have been few studies on the relationship between
VEGF-C and other malignant diseases (Ohta et al, 1999; Tsurusaki
et al, 1999; Valtola et al, 1999; Yonemura et al, 1999), and we find
no documentation of the relationship between colorectal cancer
and the immunohistochemical expression of VEGF-C. We
obtained evidence that VEGF-C is expressed in the cytoplasm of
colorectal cancer cells, findings consistent with reported data
(Yonemura et al, 1999). In cases of gastric cancer, the expression
of VEGF-C, determined using RT-PCR and immunohistochem-
istry, was strongly associated with lymph nodes metastasis and
patients with a high expression of VEGF-C protein had a signifi-
cantly poorer prognosis than those with low VEGF-C expression
(Yonemura et al, 1999). In cases of human malignant mesothe-
lioma tumours, a strong association between microlymphatic
vessel density and VEGF-C mRNA expression was also observed,
however, expression of VEGF-C showed no correlation with
lymph nodes metastasis and prognosis (Ohta et al, 1999). In cases
of human prostatic carcinoma, the expression of VEGF-C, exam-
ined using the situ hybridization, showed that VEGF-C mRNA
was significantly stronger in the lymph node-positive group than
in the lymph node-negative group (Tsurusaki et al, 1999). Our
findings that VEGF-C is associated with lymphangiogenesis in
colorectal cancer are consistent with these previous results.
The VEGF family is mediated by three known tyrosine kinase
receptors, VEGFR-1, 2, and 3. VEGF is a ligand for VEGFR-1
(Flt-1) and 2 (KDR/Flk-1) (Ferrara and Davis-Smyth, 1997).
VEGFR-2 leads to proliferation and migration of endothelial cells,
inducing angiogenesis. On the other hand, VEGFR-1 cannot
induce angiogenesis when stimulated with VEGF (Landgren et al,
1998). VEGFR-1 (Flt-1) and 2 (KDR/Flk-1) are expressed on
vascular endothelial cells (Ferrara and Davis-Smyth, 1997).
VEGFR-3 differs from VEGFR-1 and VEGFR-2 in that it is
mainly expressed in the endothelium of lymphatic vessels (Kukk
et al, 1996), which means that it may be specific marker for
lymphatic endothelial cells. VEGF-C is a ligand for VEGFR-3
(Joukov et al, 1996), and is thought to be a specific factor inducing
lymphangiogenesis. Overexpression of VEGF-C in the skin of
transgenic mice resulted in lymphatic endothelial proliferation and
vessel enlargement (Jeltsch et al, 1997). Furthermore, VEGF-C
was found to have a specific function in lymphangiogenesis.
Therefore, the increased expression of VEGF-C in colorectal
cancer with lymph nodes metastasis may be due to the specific
function of VEGF-C in lymphangiogenesis.
As VEGF-C is also a ligand for VEGFR-2, it may have angio-
genic effects. In the present study, CD34 immunostaining was
done to measure numbers of microvessels. However, we observed
no significant difference in these numbers between VEGF-C posi-
tive and negative groups, which indicates that VEGF-C has little
or no angiogenic effect, at least, in colorectal cancer.
We also tried to measure lymphatic vessel numbers using
VEGFR-3 immunohistochemistry because it had been considered
to be the only specific marker for lymphatic endothelial cells.
However, VEGFR-3 expression was recognized in the endothe-
lium of blood vessels as well as in that of lymphatic vessels (those
vessels had previously been identified by H.E. staining). Thus, it
seems unlikely that VEGFR-3 is a specific marker for lymphatic
vessels. This finding parallels data of other investigators (Partanen
et al, 1999). A more sensitive way to detect lymphatic vessels has
to be designed.
We also noted the correlation between expression of VEGF-C
and depth of the tumour. As a tumour penetrates, it is more likely
to make contact with lymphatic vessels in the submucosal layer.
Therefore, whether the increased expression of VEGF-C with
tumour depth is due to the malignant potential of tumour invasion
to the deep layer or to the increased potential of lymphangio-
genesis secondary to tumour growth has to be determined.
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Figure 3 Expression of VEGF-C mRNA in representative cases of VEGF-C protein positive group (cases 1–3) and negative one (cases 4, 5). T, tumour tissue;
N, normal tissue. GAPDH is used as an intermal control. Expression was measured using RT-PCRIn the multivariate analyses, the potential of venous involve-
ment was closely related to that of lymphatic involvement.
Molecular mechanisms differ between venous and lymphatic
involvement of cancer cells. For example, VEGF is related to
venous involvement (Kitadai et al, 1998) and VEGF-C to
lymphatic involvement (Yonemura et al, 1999). However, these
tumour advances were commonly and concomitantly noted in
clinical colorectal cancers (Tsuchiya et al, 1995).
Survival rates were poorer in VEGF-C positive groups than in
VEGF-C negative ones, but the difference was not statistically
significant. VEGF-C, which is closely related to lymph nodes
metastasis, may influence survival rates. However, hematogenous
metastasis, such as liver metastasis, is also an important factor for
survival rates of colorectal cancer patients (Scheele et al, 1990;
Sugihara et al, 1993). Therefore, in contrast to another study
(Yonemura et al, 1999), VEGF-C may not statistically influence
survival rates in colorectal cancer patients.
As VEGF-C expression is associated with lymph nodes metas-
tasis in colorectal cancer patients, this expression may aid in
detecting lymphatic spread, such as lymphatic involvement and
lymph nodes metastasis.
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